Voriconazole Pharmacokinetics in Critically Ill Patients and Extracorporeal Membrane Oxygenation Support: A Retrospective Comparative Case-Control Study

Voriconazole, an antifungal agent, displays high intra- and inter-individual variability. The predictive pharmacokinetic (PK) index requires a minimum plasma concentration (C(min)) in patient serum of between 1–5.5 mg/L. It is common to encounter fungal infections in patients undergoing extracorporeal membrane oxygenation (ECMO) support, and data regarding voriconazole PK changes during ECMO are scarce. Our study compared voriconazole PKs in patients with and without ECMO support in a retrospective cohort of critically-ill patients. Fifteen patients with 26 voriconazole C(min) determinations in the non-ECMO group and nine patients with 27 voriconazole C(min) determinations in the ECMO group were recruited. The ECMO group had lower C(min) (0.38 ± 2.98 vs. 3.62 ± 3.88, p < 0.001) and higher infratherapeutic C(min) values (16 vs. 1, p < 0.001) than the non-ECMO group. Multivariate analysis identified ECMO support (−0.668, CI(95) −0.978–−0.358) and plasma albumin levels (−0.023, CI(95) −0.046–−0.001) as risk factors for low C(min) values. When comparing pre- and post-therapeutic drug optimisation samples from the ECMO group, the dose required to achieve therapeutic C(min) was 6.44 mg/kg twice a day. Therapeutic drug optimisation is essential to improve target attainment.